CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer

Ultrastructural Pathology

Volumn 36, Issue 3, 2012, Pages 145-152

  Omran, Ola M ^a,c   Ata, Hesham S ^b  

^a Assiut University   (Egypt)

^b QASSIM UNIVERSITY   (Saudi Arabia)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

CD44s; CD44v6; Cell adhesion; Immunohistochemistry; Squamous cell carcinoma; Transitional cell carcinoma

Indexed keywords

CD44S ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLADDER TUMOR; CANCER INVASION; CELL ADHESION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PARASITOLOGY; PATHOLOGY; PROGNOSIS; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; ULTRASTRUCTURE; UROTHELIUM;

ADULT; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SCHISTOSOMIASIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84860695288     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913123.2011.651522     Document Type: Article

References (45)

1. Engeler DS, Schmid H P. [Bladder carcinoma-a current review]. Schweiz Rundsch Med Prax. 2003 Jan 22;92(4):117-126.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4): 225-249.
3. Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75 (suppl):316.
4. Khan AR, Hussain NK, Al-Saigh A, Malatani T, Sheikha AA. Pattern of cancer at Asir Central Hospital, Abha, Saudi Arabia. Ann Saudi Med. 1991 Nov;11:285-288.
5. Al-Othman K, Al-Hathal N. Pattern of management of urologic cancer in Saudi Arabia. Urol Ann. 2010 Jan;2(1): 21-25.
6. Saudi National Tumor Registry (NCR) 2004. Available from: www.emro.who.int/ncd/pdf/saa-cancer-registry-2004
7. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer. 1977 Sep;40(3):1246-1268. (Pubitemid 8219482)
8. Fedewa SA, Soliman AS, Ismail K, et al. Incidence analyses of bladder cancer in the Nile delta region of Egypt. Cancer Epidemiol. 2009 Oct;33(3-4):176-181.
9. Youssef R, Kapur P, Kabbani W, et al. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. BJU Int. 2011;108:(1):31-37.
10. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000 Feb 7;148(3):399-404.
11. Sato S, Miyauchi M, Kato M, et al. Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells. Pathobiology. 2004;71(4):171-175. (Pubitemid 38969874)
12. Springer TA. Traffc signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994 Jan 28;76(2):301-314. (Pubitemid 24046692)
13. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998 Aug;51(4):191-200. (Pubitemid 28394267)
14. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. (Pubitemid 36077255)
15. Gunthert U, Hofmann M, Rudy W, et al. A new variant of gly-coprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991 Apr 5;65(1):13-24. (Pubitemid 121001209)
16. Harada N, Mizoi T, Kinouchi M, et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer. 2001 Jan 1;91(1):67-75.
17. Fujisaki T, Tanaka Y, Fujii K, et al. CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res. 1999 Sep 1;59(17):4427-4434. (Pubitemid 29418764)
18. Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK. CD44s expression in human colon carcinomas infuences growth of liver metastases. Int J Cancer. 2000 Feb 15;85(4): 523-526. (Pubitemid 30075131)
19. Salmi M, Grön-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing iso-forms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol. 1993 Jul;122(2):431-442. (Pubitemid 23210469)
20. Ponta H, Sleeman J, Dall P, Moll J, Sherman L, Herrlich P. CD44 isoforms in metastatic cancer. Invasion Metastasis. 1995;14:82-86.
21. da Cunha CB, Oliveira C, Wen X, et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest. 2010 Nov;90(11):1604-1614.
22. Yang S, Wang HP, Wang XY, et al. Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex pleomor-phic adenoma. Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S101-S108.
23. Yu P, Zhou L, Ke W, Li K. Clinical signifcance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol. 2010 Aug;136(8):1283-1292.
24. Sun Y, He DL, Ma Q, et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Eng). 2006;119(21):1763-1771. (Pubitemid 44768604)
25. Gontero P, Banisadr S, Frea B, Brausi M. Metastatic markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol. 2004;40:296-307.
26. Kuncova J, Kostrouch Z, Viale M, Revoltella R, Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol. 2005;51:3-11. (Pubitemid 40372915)
27. Sobin LH, Wittekind C, International Union Against Cancer (UICC). Urinary bladder. In TNM: Classifcation of Malignant Tumors. New York: Wiley-Liss; 1997: 187-190.
28. Epstein JI, Amin MB, Reuter VR, Mostof FK. The Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus classifcation of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998; 22:1435.
29. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 1998 Oct;186(2):157-164. (Pubitemid 28467825)
30. Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci. 1998 Jul 1;3:e89-109.
31. Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer. 1995 Aug 9;62(4):449-456.
32. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett. 1995 Feb;89(1):81-87.
33. Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol. 1995 Jun;153(6):2025-2028.
34. Gadalla HA, Kamel NA, Badary FA, Elanany FG. Expression of CD44 protein in bilharzial and non-bilharzial bladder cancers. BJU Int. 2004 Jan;93(1):151-155. (Pubitemid 38112986)
35. Woodman AC, Goodison S, Drake M, Noble J, Tarin D. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 iso-forms in exfoliated urothelia. Clin Cancer Res. 2000 Jun;6 (6):2381-2392. (Pubitemid 30399206)
36. Ross JS, del Rosario AD, Bui HX, Kallakury BV, Okby NT, Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996 Aug;9 (8):854-860. (Pubitemid 26279277)
37. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996 Sep;149 (3):873-882. (Pubitemid 26334171)
38. Toma V, Hauri D, Schmid U, et al. Focal loss of CD44 variant protein expression is related to recurrence in superfcial bladder carcinoma. Am J Pathol. 1999;155(5):1427-1432.
39. Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res. 1997 Jun 1;57(11):2281-2289. (Pubitemid 27247050)
40. Franzmann EJ, Weed DT, Civantos FJ, Goodwin WJ, Bourguignon LY. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression. Otolaryngol Head Neck Surg. 2001 Apr;124 (4):426-432. (Pubitemid 33587105)
41. Rodrigo JP, Dominguez F, Alvarez C, Gonzalez MV, Herrero A, Suarez C. Clinicopathologic signifcance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002 Jul;118(1):67-72. (Pubitemid 34734254)
42. Ioachim E, Assimakopoulos D, Goussia AC, Peschos D, Skevas A, Agnantis NJ. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol Histopathol. 1999 Oct;14(4):1113-1118. (Pubitemid 29447452)
43. Sikorska B, Danilewicz M, Wagrowska-Danilewicz M. Prognostic signifcance of CD44v6 and nm23 protein immunoexpression in laryngeal squamous cell carcinoma. Pol J Pathol. 2002;53(1):17-24. (Pubitemid 34534939)
44. Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T, Summers JL. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol. 2010 May;34(3):140-160.
45. Lü X, Xu K, Lü H, et al. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol. 2011 Apr;35(2):72-78.